Progyny, Inc. Announces Third Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Progyny (PGNY) Tops Q3 EPS by 1c, Revenues Beat; Offers Q4 & FY19 EPS/Revenue Guidance
December 4, 2019 4:08 PM ESTProgyny (NASDAQ: PGNY) reported Q3 EPS of $0.03, $0.01 better than the analyst estimate of $0.02. Revenue for the quarter came in at $61.2 million versus the consensus estimate of $60.77 million.
Progyny has redefined the market for employer-sponsored fertility benefits, demonstrating that it is possible to simultaneously create a great patient experience, generate superior clinical outcomes, and provide for a more efficient use of employer healthcare dollars to address a health condition that affects millions, said David Schlanger, Chief Executive Officer of Progyny. Our vision is to ensure that anyone can have a child, and we are... More
